邁克生物(300463.SZ)業績快報:2020年度淨利潤升51.43%至7.95億元
格隆匯 2 月 25日丨邁克生物(300463.SZ)發佈2020年度業績快報,實現營業總收入37.04億元,同比增長14.91%;營業利潤10.03億元,同比增長44.07%;歸屬於上市公司股東的淨利潤7.95億元,同比增長51.43%;基本每股收益1.4303元。
報吿期內,公司經營業績增長主要系公司在新冠疫情爆發之初,積極組織研發力量快速研發出新冠核酸檢測和抗體檢測等產品,隨着2020年新冠疫情在全球的持續爆發,公司分子診斷、快速檢測平台的新冠檢測產品銷售迅速增長。同時隨着國內疫情防控成果不斷鞏固,公司常規檢測產品的銷售穩步恢復。通過公司國內銷售渠道優化以及海外渠道的拓展,自主產品銷售快速增長,促使公司2020年度經營業績呈現良好向上的態勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.